<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20240723141243&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20240723141243&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 23 Jul 2024 18:12:44 +0000</lastbuilddate>
<pubDate>Tue, 23 Jul 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>SGLT2 Inhibitors Act Independently of &lt;em>;SGLT2&lt;/em>; to Confer Benefit for HFrEF in Mice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39041214/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240723141243&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 23. doi: 10.1161/CIRCRESAHA.124.324823. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39041214/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240723141243&v=2.18.0.post9+e462414">39041214</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324823>10.1161/CIRCRESAHA.124.324823</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39041214</guid>
<pubDate>Tue, 23 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Justin H Berger</dc:creator>
<dc:creator>Timothy R Matsuura</dc:creator>
<dc:creator>Caitlyn E Bowman</dc:creator>
<dc:creator>Renee Taing</dc:creator>
<dc:creator>Jiten Patel</dc:creator>
<dc:creator>Ling Lai</dc:creator>
<dc:creator>Teresa C Leone</dc:creator>
<dc:creator>Jeffrey D Reagan</dc:creator>
<dc:creator>Saptarsi M Haldar</dc:creator>
<dc:creator>Zoltan Arany</dc:creator>
<dc:creator>Daniel P Kelly</dc:creator>
<dc:date>2024-07-23</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>SGLT2 Inhibitors Act Independently of &lt;em>;SGLT2&lt;/em>; to Confer Benefit for HFrEF in Mice</dc:title>
<dc:identifier>pmid:39041214</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324823</dc:identifier>
</item>
<item>
<title>'Caterpillar-like' pseudoaneurysms in Behçet's disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39041184/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240723141243&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 23:ehae448. doi: 10.1093/eurheartj/ehae448. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39041184/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240723141243&v=2.18.0.post9+e462414">39041184</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae448>10.1093/eurheartj/ehae448</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39041184</guid>
<pubDate>Tue, 23 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jinting Ge</dc:creator>
<dc:creator>Tiehao Wang</dc:creator>
<dc:creator>Ding Yuan</dc:creator>
<dc:date>2024-07-23</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>'Caterpillar-like' pseudoaneurysms in Behçet's disease</dc:title>
<dc:identifier>pmid:39041184</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae448</dc:identifier>
</item>
<item>
<title>Cardiac sarcomere turnover by unidirectional replacement of proteins</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39039179/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240723141243&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jul 22. doi: 10.1038/s41569-024-01065-3. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39039179/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240723141243&v=2.18.0.post9+e462414">39039179</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01065-3>10.1038/s41569-024-01065-3</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39039179</guid>
<pubDate>Mon, 22 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Gregory B Lim</dc:creator>
<dc:date>2024-07-22</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Cardiac sarcomere turnover by unidirectional replacement of proteins</dc:title>
<dc:identifier>pmid:39039179</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01065-3</dc:identifier>
</item>
<item>
<title>Standardization and clinical applications of retinal imaging biomarkers for cardiovascular disease: a Roadmap from an NHLBI workshop</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39039178/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240723141243&amp;v=2.18.0.post9+e462414
      <description>The accessibility of the retina with the use of non-invasive and relatively low-cost ophthalmic imaging techniques and analytics provides a unique opportunity to improve the detection, diagnosis and monitoring of systemic diseases. The National Heart, Lung, and Blood Institute conducted a workshop in October 2022 to examine this concept. On the basis of the discussions at that workshop, this Roadmap describes current knowledge gaps and new research opportunities to evaluate the relationships...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jul 22. doi: 10.1038/s41569-024-01060-8. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The accessibility of the retina with the use of non-invasive and relatively low-cost ophthalmic imaging techniques and analytics provides a unique opportunity to improve the detection, diagnosis and monitoring of systemic diseases. The National Heart, Lung, and Blood Institute conducted a workshop in October 2022 to examine this concept. On the basis of the discussions at that workshop, this Roadmap describes current knowledge gaps and new research opportunities to evaluate the relationships between the eye (in particular, retinal biomarkers) and the risk of cardiovascular diseases, including coronary artery disease, heart failure, stroke, hypertension and vascular dementia. Identified gaps include the need to simplify and standardize the capture of high-quality images of the eye by non-ophthalmic health workers and to conduct longitudinal studies using multidisciplinary networks of diverse at-risk populations with improved implementation and methods to protect participant and dataset privacy. Other gaps include improving the measurement of structural and functional retinal biomarkers, determining the relationship between microvascular and macrovascular risk factors, improving multimodal imaging 'pipelines', and integrating advanced imaging with 'omics', lifestyle factors, primary care data and radiological reports, by using artificial intelligence technology to improve the identification of individual-level risk. Future research on retinal microvascular disease and retinal biomarkers might additionally provide insights into the temporal development of microvascular disease across other systemic vascular beds.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39039178/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240723141243&v=2.18.0.post9+e462414">39039178</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01060-8>10.1038/s41569-024-01060-8</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39039178</guid>
<pubDate>Mon, 22 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Emily Y Chew</dc:creator>
<dc:creator>Stephen A Burns</dc:creator>
<dc:creator>Alison G Abraham</dc:creator>
<dc:creator>Mathieu F Bakhoum</dc:creator>
<dc:creator>Joshua A Beckman</dc:creator>
<dc:creator>Toco Y P Chui</dc:creator>
<dc:creator>Robert P Finger</dc:creator>
<dc:creator>Alejandro F Frangi</dc:creator>
<dc:creator>Rebecca F Gottesman</dc:creator>
<dc:creator>Maria B Grant</dc:creator>
<dc:creator>Henner Hanssen</dc:creator>
<dc:creator>Cecilia S Lee</dc:creator>
<dc:creator>Michelle L Meyer</dc:creator>
<dc:creator>Damiano Rizzoni</dc:creator>
<dc:creator>Alicja R Rudnicka</dc:creator>
<dc:creator>Joel S Schuman</dc:creator>
<dc:creator>Sara B Seidelmann</dc:creator>
<dc:creator>W H Wilson Tang</dc:creator>
<dc:creator>Bishow B Adhikari</dc:creator>
<dc:creator>Narasimhan Danthi</dc:creator>
<dc:creator>Yuling Hong</dc:creator>
<dc:creator>Diane Reid</dc:creator>
<dc:creator>Grace L Shen</dc:creator>
<dc:creator>Young S Oh</dc:creator>
<dc:date>2024-07-22</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Standardization and clinical applications of retinal imaging biomarkers for cardiovascular disease: a Roadmap from an NHLBI workshop</dc:title>
<dc:identifier>pmid:39039178</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01060-8</dc:identifier>
</item>
<item>
<title>RNA Editing Holds Promise for Hypertrophic Cardiomyopathy Therapy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39038091/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240723141243&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 23;150(4):299-301. doi: 10.1161/CIRCULATIONAHA.124.070137. Epub 2024 Jul 22.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39038091/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240723141243&v=2.18.0.post9+e462414">39038091</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070137>10.1161/CIRCULATIONAHA.124.070137</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39038091</guid>
<pubDate>Mon, 22 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Lucie Carrier</dc:creator>
<dc:date>2024-07-22</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>RNA Editing Holds Promise for Hypertrophic Cardiomyopathy Therapy</dc:title>
<dc:identifier>pmid:39038091</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070137</dc:identifier>
</item>
<item>
<title>Misdiagnosis From a Smart Watch</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39038090/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240723141243&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 23;150(4):340-342. doi: 10.1161/CIRCULATIONAHA.124.068979. Epub 2024 Jul 22.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39038090/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240723141243&v=2.18.0.post9+e462414">39038090</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068979>10.1161/CIRCULATIONAHA.124.068979</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39038090</guid>
<pubDate>Mon, 22 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Yaanik B Desai</dc:creator>
<dc:creator>Nitish Badhwar</dc:creator>
<dc:date>2024-07-22</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Misdiagnosis From a Smart Watch</dc:title>
<dc:identifier>pmid:39038090</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068979</dc:identifier>
</item>
<item>
<title>Illness Trajectories After Revascularization in Patients With Peripheral Artery Disease: A Unified Approach to Understanding the Risk of Major Amputation and Death</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39038089/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240723141243&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The illness-death model provides an integrated framework to understand patient outcomes after lower limb revascularization for PAD. Although mortality increased with age, the study highlights patients &lt;60 years of age were at increased risk of major amputation, particularly after nonelective revascularization.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 23;150(4):261-271. doi: 10.1161/CIRCULATIONAHA.123.067687. Epub 2024 Jul 22.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The aim of this study was to investigate the illness trajectories of patients with peripheral artery disease (PAD) after revascularization and estimate the independent risks of major amputation and death (from any cause) and their interaction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Data from Hospital Episode Statistics Admitted Patient Care were used to identify patients (≥50 years of age) who underwent lower limb revascularization for PAD in England from April 2013 to March 2020. A Markov illness-death model was developed to describe patterns of survival after the initial lower limb revascularization, if and when patients experienced major amputation, and survival after amputation. The model was also used to investigate the association between patient characteristics and these illness trajectories. We also analyzed the relative contribution of deaths after amputation to overall mortality and how the risk of mortality after amputation was related to the time from the index revascularization to amputation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study analyzed 94 690 patients undergoing lower limb revascularization for PAD from 2013 to 2020. The majority were men (65.6%), and the median age was 72 years (interquartile range, 64-79). One-third (34.8%) of patients had nonelective revascularization, whereas others had elective procedures. For nonelective patients, the amputation rate was 15.2% (95% CI, 14.4-16.0) and 19.9% (19.0-20.8) at 1 and 5 years after revascularization, respectively. For elective patients, the corresponding amputation rate was 2.7% (95% CI, 2.4-3.1) and 5.3% (4.9-5.8). Overall, the risk of major amputation was higher among patients who were younger, had tissue loss, diabetes, greater frailty, nonelective revascularization, and more distal procedures. The mortality rate at 5 years after revascularization was 64.3% (95% CI, 63.2-65.5) for nonelective patients and 33.0% (32.0-34.1) for elective patients. After major amputation, patients were at an increased risk of mortality if they underwent major amputation within 6 months after the index revascularization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The illness-death model provides an integrated framework to understand patient outcomes after lower limb revascularization for PAD. Although mortality increased with age, the study highlights patients &lt;60 years of age were at increased risk of major amputation, particularly after nonelective revascularization.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39038089/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240723141243&v=2.18.0.post9+e462414">39038089</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067687>10.1161/CIRCULATIONAHA.123.067687</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39038089</guid>
<pubDate>Mon, 22 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Qiuju Li</dc:creator>
<dc:creator>Panagiota Birmpili</dc:creator>
<dc:creator>Eleanor Atkins</dc:creator>
<dc:creator>Amundeep S Johal</dc:creator>
<dc:creator>Sam Waton</dc:creator>
<dc:creator>Robin Williams</dc:creator>
<dc:creator>Jonathan R Boyle</dc:creator>
<dc:creator>Denis W Harkin</dc:creator>
<dc:creator>Arun D Pherwani</dc:creator>
<dc:creator>David A Cromwell</dc:creator>
<dc:date>2024-07-22</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Illness Trajectories After Revascularization in Patients With Peripheral Artery Disease: A Unified Approach to Understanding the Risk of Major Amputation and Death</dc:title>
<dc:identifier>pmid:39038089</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067687</dc:identifier>
</item>
<item>
<title>Global Collaborative Cardiovascular Research: The Collective Wisdom of Countries</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39038088/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240723141243&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 23;150(4):258-260. doi: 10.1161/CIRCULATIONAHA.124.068235. Epub 2024 Jul 22.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39038088/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240723141243&v=2.18.0.post9+e462414">39038088</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.068235>10.1161/CIRCULATIONAHA.124.068235</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39038088</guid>
<pubDate>Mon, 22 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Paul W Armstrong</dc:creator>
<dc:date>2024-07-22</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Global Collaborative Cardiovascular Research: The Collective Wisdom of Countries</dc:title>
<dc:identifier>pmid:39038088</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.068235</dc:identifier>
</item>
<item>
<title>Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39038086/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240723141243&amp;v=2.18.0.post9+e462414
      <description>For almost two decades, 12-month dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) has been the only class I recommendation on DAPT in American and European guidelines, which has resulted in 12-month durations of DAPT therapy being the most frequently implemented in ACS patients undergoing percutaneous coronary intervention (PCI) across the globe. Twelve-month DAPT was initially grounded in the results of the CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events)...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Jul 23;150(4):317-335. doi: 10.1161/CIRCULATIONAHA.124.069012. Epub 2024 Jul 22.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">For almost two decades, 12-month dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) has been the only class I recommendation on DAPT in American and European guidelines, which has resulted in 12-month durations of DAPT therapy being the most frequently implemented in ACS patients undergoing percutaneous coronary intervention (PCI) across the globe. Twelve-month DAPT was initially grounded in the results of the CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events) trial, which, by design, studied DAPT versus no DAPT rather than the optimal DAPT duration. The average DAPT duration in this study was 9 months, not 12 months. Subsequent ACS studies, which were not designed to assess DAPT duration, rather its composition (aspirin with prasugrel or ticagrelor compared with clopidogrel) were further interpreted as supportive evidence for 12-month DAPT duration. In these studies, the median DAPT duration was 9 or 15 months for ticagrelor and prasugrel, respectively. Several subsequent studies questioned the 12-month regimen and suggested that DAPT duration should either be fewer than 12 months in patients at high bleeding risk or more than 12 months in patients at high ischemic risk who can safely tolerate the treatment. Bleeding, rather than ischemic risk assessment, has emerged as a treatment modifier for maximizing the net clinical benefit of DAPT, due to excessive bleeding and no clear benefit of prolonged treatment regimens in high bleeding risk patients. Multiple DAPT de-escalation treatment strategies, including switching from prasugrel or ticagrelor to clopidogrel, reducing the dose of prasugrel or ticagrelor, and shortening DAPT duration while maintaining monotherapy with ticagrelor, have been consistently shown to reduce bleeding without increasing fatal or nonfatal cardiovascular or cerebral ischemic risks compared with 12-month DAPT. However, 12-month DAPT remains the only class-I DAPT recommendation for patients with ACS despite the lack of prospectively established evidence, leading to unnecessary and potentially harmful overtreatment in many patients. It is time for clinical practice and guideline recommendations to be updated to reflect the totality of the evidence regarding the optimal DAPT duration in ACS.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39038086/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240723141243&v=2.18.0.post9+e462414">39038086</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069012>10.1161/CIRCULATIONAHA.124.069012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39038086</guid>
<pubDate>Mon, 22 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Marco Valgimigli</dc:creator>
<dc:creator>Antonio Landi</dc:creator>
<dc:creator>Dominick J Angiolillo</dc:creator>
<dc:creator>Usman Baber</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Marc P Bonaca</dc:creator>
<dc:creator>Davide Capodanno</dc:creator>
<dc:creator>David J Cohen</dc:creator>
<dc:creator>C Michael Gibson</dc:creator>
<dc:creator>Stefan James</dc:creator>
<dc:creator>Takeshi Kimura</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Shamir R Mehta</dc:creator>
<dc:creator>Gilles Montalescot</dc:creator>
<dc:creator>Dirk Sibbing</dc:creator>
<dc:creator>P Gabriel Steg</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Robert F Storey</dc:creator>
<dc:creator>Pascal Vranckx</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:date>2024-07-22</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome</dc:title>
<dc:identifier>pmid:39038086</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069012</dc:identifier>
</item>
<item>
<title>Biological and Procedural Predictors of Outcome in the Stroke Preclinical Assessment Network (SPAN) Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39034919/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240723141243&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our analyses identified variables affecting endovascular filament MCAo outcome, an experimental stroke model used worldwide. Multiple regression refuted some commonly reported predictors and revealed previously unrecognized associations. Given the multicenter prospective design that represents a sampling of real-world conditions, the degree of heterogeneity mimicking clinical trials, the large number of predictors adjusted for in the multivariable model, and the large sample size,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jul 22. doi: 10.1161/CIRCRESAHA.123.324139. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The SPAN trial (Stroke Preclinical Assessment Network) is the largest preclinical study testing acute stroke interventions in experimental focal cerebral ischemia using endovascular filament middle cerebral artery occlusion (MCAo). Besides testing interventions against controls, the prospective design captured numerous biological and procedural variables, highlighting the enormous heterogeneity introduced by the multicenter structure that might influence stroke outcomes. Here, we leveraged the unprecedented sample size achieved by the SPAN trial and the prospective design to identify the biological and procedural variables that affect experimental stroke outcomes in transient endovascular filament MCAo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The study cohort included all mice enrolled and randomized in the SPAN trial (N=1789). Mice were subjected to 60-minute MCAo and followed for a month. Thirteen biological and procedural independent variables and 4 functional (weight loss and 4-point neuroscore on days 1 and 2, corner test on days 7 and 28, and mortality) and 3 tissue (day 2, magnetic resonance imaging infarct volumes and swelling; day 30, magnetic resonance imaging tissue loss) outcome variables were prospectively captured. Multivariable regression with stepwise elimination was used to identify the predictors and their effect sizes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Older age, active circadian stage at MCAo, and thinner and longer filament silicone tips predicted higher mortality. Older age, larger body weight, longer anesthesia duration, and longer filament tips predicted worse neuroscores, while high-fat diet and blood flow monitoring predicted milder neuroscores. Older age and a high-fat diet predicted worse corner test performance. While shorter filament tips predicted more ipsiversive turning, longer filament tips appeared to predict contraversive turning. Age, sex, and weight interacted when predicting the infarct volume. Older age was associated with smaller infarcts on day 2 magnetic resonance imaging, especially in animals with larger body weights; this association was most conspicuous in females. High-fat diet also predicted smaller infarcts. In contrast, the use of cerebral blood flow monitoring and more severe cerebral blood flow drop during MCAo, longer anesthesia, and longer filament tips all predicted larger infarcts. Bivariate analyses among the dependent variables highlighted a disconnect between tissue and functional outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our analyses identified variables affecting endovascular filament MCAo outcome, an experimental stroke model used worldwide. Multiple regression refuted some commonly reported predictors and revealed previously unrecognized associations. Given the multicenter prospective design that represents a sampling of real-world conditions, the degree of heterogeneity mimicking clinical trials, the large number of predictors adjusted for in the multivariable model, and the large sample size, we think this is the most definitive analysis of the predictors of preclinical stroke outcome to date. Future multicenter experimental stroke trials should standardize or at least ensure a balanced representation of the biological and procedural variables identified herein as potential confounders.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39034919/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240723141243&v=2.18.0.post9+e462414">39034919</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.324139>10.1161/CIRCRESAHA.123.324139</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39034919</guid>
<pubDate>Mon, 22 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Andreia Morais</dc:creator>
<dc:creator>Takahiko Imai</dc:creator>
<dc:creator>Xuyan Jin</dc:creator>
<dc:creator>Joseph J Locascio</dc:creator>
<dc:creator>Ligia Boisserand</dc:creator>
<dc:creator>Alison L Herman</dc:creator>
<dc:creator>Anjali Chauhan</dc:creator>
<dc:creator>Jessica Lamb</dc:creator>
<dc:creator>Karisma Nagarkatti</dc:creator>
<dc:creator>Marcio A Diniz</dc:creator>
<dc:creator>Mariia Kumskova</dc:creator>
<dc:creator>Nirav Dhanesha</dc:creator>
<dc:creator>Pradip K Kamat</dc:creator>
<dc:creator>Mohammad Badruzzaman Khan</dc:creator>
<dc:creator>Krishnan M Dhandapani</dc:creator>
<dc:creator>Rakesh B Patel</dc:creator>
<dc:creator>Brijesh Sutariya</dc:creator>
<dc:creator>Yanrong Shi</dc:creator>
<dc:creator>Klaus van Leyen</dc:creator>
<dc:creator>W Taylor Kimberly</dc:creator>
<dc:creator>David C Hess</dc:creator>
<dc:creator>Jaroslaw Aronowski</dc:creator>
<dc:creator>Enrique C Leira</dc:creator>
<dc:creator>Raymond C Koehler</dc:creator>
<dc:creator>Anil K Chauhan</dc:creator>
<dc:creator>Lauren H Sansing</dc:creator>
<dc:creator>Patrick D Lyden</dc:creator>
<dc:creator>Cenk Ayata</dc:creator>
<dc:date>2024-07-22</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Biological and Procedural Predictors of Outcome in the Stroke Preclinical Assessment Network (SPAN) Trial</dc:title>
<dc:identifier>pmid:39034919</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.324139</dc:identifier>
</item>
<item>
<title>Discovery of deaminase functions by structure-based protein clustering</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39033754/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240723141243&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jul 20:S0092-8674(24)00718-9. doi: 10.1016/j.cell.2024.07.003. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39033754/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240723141243&v=2.18.0.post9+e462414">39033754</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.003>10.1016/j.cell.2024.07.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39033754</guid>
<pubDate>Sun, 21 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Jiaying Huang</dc:creator>
<dc:creator>Qiupeng Lin</dc:creator>
<dc:creator>Hongyuan Fei</dc:creator>
<dc:creator>Zixin He</dc:creator>
<dc:creator>Hu Xu</dc:creator>
<dc:creator>Yunjia Li</dc:creator>
<dc:creator>Kunli Qu</dc:creator>
<dc:creator>Peng Han</dc:creator>
<dc:creator>Qiang Gao</dc:creator>
<dc:creator>Boshu Li</dc:creator>
<dc:creator>Guanwen Liu</dc:creator>
<dc:creator>Lixiao Zhang</dc:creator>
<dc:creator>Jiacheng Hu</dc:creator>
<dc:creator>Rui Zhang</dc:creator>
<dc:creator>Erwei Zuo</dc:creator>
<dc:creator>Yonglun Luo</dc:creator>
<dc:creator>Yidong Ran</dc:creator>
<dc:creator>Jin-Long Qiu</dc:creator>
<dc:creator>Kevin Tianmeng Zhao</dc:creator>
<dc:creator>Caixia Gao</dc:creator>
<dc:date>2024-07-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Discovery of deaminase functions by structure-based protein clustering</dc:title>
<dc:identifier>pmid:39033754</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.003</dc:identifier>
</item>
<item>
<title>Focus on acute myocardial infarction, sex-related differences in coronary bypass surgery, inflammation in heart failure, and infective endocarditis in prosthetic valves</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39032925/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240723141243&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 21;45(28):2463-2467. doi: 10.1093/eurheartj/ehae450.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39032925/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240723141243&v=2.18.0.post9+e462414">39032925</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae450>10.1093/eurheartj/ehae450</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39032925</guid>
<pubDate>Sat, 20 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-07-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Focus on acute myocardial infarction, sex-related differences in coronary bypass surgery, inflammation in heart failure, and infective endocarditis in prosthetic valves</dc:title>
<dc:identifier>pmid:39032925</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae450</dc:identifier>
</item>
<item>
<title>Functional control of myosin motors in the cardiac cycle</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39030271/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240723141243&amp;v=2.18.0.post9+e462414
      <description>Contraction of the heart is driven by cyclical interactions between myosin and actin filaments powered by ATP hydrolysis. The modular structure of heart muscle and the organ-level synchrony of the heartbeat ensure tight reciprocal coupling between this myosin ATPase cycle and the macroscopic cardiac cycle. The myosin motors respond to the cyclical activation of the actin and myosin filaments to drive the pressure changes that control the inflow and outflow valves of the heart chambers. Opening...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jul 19. doi: 10.1038/s41569-024-01063-5. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Contraction of the heart is driven by cyclical interactions between myosin and actin filaments powered by ATP hydrolysis. The modular structure of heart muscle and the organ-level synchrony of the heartbeat ensure tight reciprocal coupling between this myosin ATPase cycle and the macroscopic cardiac cycle. The myosin motors respond to the cyclical activation of the actin and myosin filaments to drive the pressure changes that control the inflow and outflow valves of the heart chambers. Opening and closing of the valves in turn switches the myosin motors between roughly isometric and roughly isotonic contraction modes. Peak filament stress in the heart is much smaller than in fully activated skeletal muscle, although the myosin filaments in the two muscle types have the same number of myosin motors. Calculations indicate that only ~5% of the myosin motors in the heart are needed to generate peak systolic pressure, although many more motors are needed to drive ejection. Tight regulation of the number of active motors is essential for the efficient functioning of the healthy heart - this control is commonly disrupted by gene variants associated with inherited heart disease, and its restoration might be a useful end point in the development of novel therapies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39030271/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240723141243&v=2.18.0.post9+e462414">39030271</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01063-5>10.1038/s41569-024-01063-5</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39030271</guid>
<pubDate>Fri, 19 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Malcolm Irving</dc:creator>
<dc:date>2024-07-19</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Functional control of myosin motors in the cardiac cycle</dc:title>
<dc:identifier>pmid:39030271</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01063-5</dc:identifier>
</item>
<item>
<title>Computational modelling of cardiovascular pathophysiology to risk stratify commercial spaceflight</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39030270/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240723141243&amp;v=2.18.0.post9+e462414
      <description>For more than 60 years, humans have travelled into space. Until now, the majority of astronauts have been professional, government agency astronauts selected, in part, for their superlative physical fitness and the absence of disease. Commercial spaceflight is now becoming accessible to members of the public, many of whom would previously have been excluded owing to unsatisfactory fitness or the presence of cardiorespiratory diseases. While data exist on the effects of gravitational and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jul 19. doi: 10.1038/s41569-024-01047-5. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">For more than 60 years, humans have travelled into space. Until now, the majority of astronauts have been professional, government agency astronauts selected, in part, for their superlative physical fitness and the absence of disease. Commercial spaceflight is now becoming accessible to members of the public, many of whom would previously have been excluded owing to unsatisfactory fitness or the presence of cardiorespiratory diseases. While data exist on the effects of gravitational and acceleration (G) forces on human physiology, data on the effects of the aerospace environment in unselected members of the public, and particularly in those with clinically significant pathology, are limited. Although short in duration, these high acceleration forces can potentially either impair the experience or, more seriously, pose a risk to health in some individuals. Rather than expose individuals with existing pathology to G forces to collect data, computational modelling might be useful to predict the nature and severity of cardiovascular diseases that are of sufficient risk to restrict access, require modification, or suggest further investigation or training before flight. In this Review, we explore state-of-the-art, zero-dimensional, compartmentalized models of human cardiovascular pathophysiology that can be used to simulate the effects of acceleration forces, homeostatic regulation and ventilation-perfusion matching, using data generated by long-arm centrifuge facilities of the US National Aeronautics and Space Administration and the European Space Agency to risk stratify individuals and help to improve safety in commercial suborbital spaceflight.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39030270/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240723141243&v=2.18.0.post9+e462414">39030270</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01047-5>10.1038/s41569-024-01047-5</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39030270</guid>
<pubDate>Fri, 19 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Paul D Morris</dc:creator>
<dc:creator>Ryan A Anderton</dc:creator>
<dc:creator>Karina Marshall-Goebel</dc:creator>
<dc:creator>Joseph K Britton</dc:creator>
<dc:creator>Stuart M C Lee</dc:creator>
<dc:creator>Nicolas P Smith</dc:creator>
<dc:creator>Frans N van de Vosse</dc:creator>
<dc:creator>Karen M Ong</dc:creator>
<dc:creator>Tom A Newman</dc:creator>
<dc:creator>Daniel J Taylor</dc:creator>
<dc:creator>Tim Chico</dc:creator>
<dc:creator>Julian P Gunn</dc:creator>
<dc:creator>Andrew J Narracott</dc:creator>
<dc:creator>D Rod Hose</dc:creator>
<dc:creator>Ian Halliday</dc:creator>
<dc:date>2024-07-19</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Computational modelling of cardiovascular pathophysiology to risk stratify commercial spaceflight</dc:title>
<dc:identifier>pmid:39030270</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01047-5</dc:identifier>
</item>
<item>
<title>Manuscript submission to European Heart Journal: easier than ever</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39028843/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240723141243&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 19:ehae260. doi: 10.1093/eurheartj/ehae260. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39028843/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240723141243&v=2.18.0.post9+e462414">39028843</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae260>10.1093/eurheartj/ehae260</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39028843</guid>
<pubDate>Fri, 19 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:creator>Alexandra Frances Kavaney</dc:creator>
<dc:date>2024-07-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Manuscript submission to European Heart Journal: easier than ever</dc:title>
<dc:identifier>pmid:39028843</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae260</dc:identifier>
</item>
<item>
<title>Periprocedural myocardial infarction: thresholds of (in)significance</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39028751/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240723141243&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 19:ehae451. doi: 10.1093/eurheartj/ehae451. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39028751/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240723141243&v=2.18.0.post9+e462414">39028751</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae451>10.1093/eurheartj/ehae451</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39028751</guid>
<pubDate>Fri, 19 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Yousif Ahmad</dc:creator>
<dc:creator>Alexandra J Lansky</dc:creator>
<dc:date>2024-07-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Periprocedural myocardial infarction: thresholds of (in)significance</dc:title>
<dc:identifier>pmid:39028751</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae451</dc:identifier>
</item>
<item>
<title>Genetic testing in early-onset atrial fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39028637/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240723141243&amp;v=2.18.0.post9+e462414
      <description>Atrial fibrillation (AF) is a globally prevalent cardiac arrhythmia with significant genetic underpinnings, as highlighted by recent large-scale genetic studies. A prominent clinical and genetic overlap exists between AF, heritable ventricular cardiomyopathies, and arrhythmia syndromes, underlining the potential of AF as an early indicator of severe ventricular disease in younger individuals. Indeed, several recent studies have demonstrated meaningful yields of rare pathogenic variants among...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 19:ehae298. doi: 10.1093/eurheartj/ehae298. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Atrial fibrillation (AF) is a globally prevalent cardiac arrhythmia with significant genetic underpinnings, as highlighted by recent large-scale genetic studies. A prominent clinical and genetic overlap exists between AF, heritable ventricular cardiomyopathies, and arrhythmia syndromes, underlining the potential of AF as an early indicator of severe ventricular disease in younger individuals. Indeed, several recent studies have demonstrated meaningful yields of rare pathogenic variants among early-onset AF patients (∼4%-11%), most notably for cardiomyopathy genes in which rare variants are considered clinically actionable. Genetic testing thus presents a promising opportunity to identify monogenetic defects linked to AF and inherited cardiac conditions, such as cardiomyopathy, and may contribute to prognosis and management in early-onset AF patients. A first step towards recognizing this monogenic contribution was taken with the Class IIb recommendation for genetic testing in AF patients aged 45 years or younger by the 2023 American College of Cardiology/American Heart Association guidelines for AF. By identifying pathogenic genetic variants known to underlie inherited cardiomyopathies and arrhythmia syndromes, a personalized care pathway can be developed, encompassing more tailored screening, cascade testing, and potentially genotype-informed prognosis and preventive measures. However, this can only be ensured by frameworks that are developed and supported by all stakeholders. Ambiguity in test results such as variants of uncertain significance remain a major challenge and as many as ∼60% of people with early-onset AF might carry such variants. Patient education (including pretest counselling), training of genetic teams, selection of high-confidence genes, and careful reporting are strategies to mitigate this. Further challenges to implementation include financial barriers, insurability issues, workforce limitations, and the need for standardized definitions in a fast-moving field. Moreover, the prevailing genetic evidence largely rests on European descent populations, underscoring the need for diverse research cohorts and international collaboration. Embracing these challenges and the potential of genetic testing may improve AF care. However, further research-mechanistic, translational, and clinical-is urgently needed.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39028637/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240723141243&v=2.18.0.post9+e462414">39028637</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae298>10.1093/eurheartj/ehae298</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39028637</guid>
<pubDate>Fri, 19 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Shinwan Kany</dc:creator>
<dc:creator>Sean J Jurgens</dc:creator>
<dc:creator>Joel T Rämö</dc:creator>
<dc:creator>Ingrid E Christophersen</dc:creator>
<dc:creator>Michiel Rienstra</dc:creator>
<dc:creator>Mina K Chung</dc:creator>
<dc:creator>Morten S Olesen</dc:creator>
<dc:creator>Michael J Ackerman</dc:creator>
<dc:creator>Elizabeth M McNally</dc:creator>
<dc:creator>Christopher Semsarian</dc:creator>
<dc:creator>Renate B Schnabel</dc:creator>
<dc:creator>Arthur A M Wilde</dc:creator>
<dc:creator>Emelia J Benjamin</dc:creator>
<dc:creator>Heidi L Rehm</dc:creator>
<dc:creator>Paulus Kirchhof</dc:creator>
<dc:creator>Connie R Bezzina</dc:creator>
<dc:creator>Dan M Roden</dc:creator>
<dc:creator>M Benjamin Shoemaker</dc:creator>
<dc:creator>Patrick T Ellinor</dc:creator>
<dc:date>2024-07-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Genetic testing in early-onset atrial fibrillation</dc:title>
<dc:identifier>pmid:39028637</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae298</dc:identifier>
</item>
<item>
<title>Pulmonary artery pressure-guided heart failure care: the setting matters</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39027970/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240723141243&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 19:ehae441. doi: 10.1093/eurheartj/ehae441. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39027970/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240723141243&v=2.18.0.post9+e462414">39027970</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae441>10.1093/eurheartj/ehae441</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39027970</guid>
<pubDate>Fri, 19 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Stefan Störk</dc:creator>
<dc:date>2024-07-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Pulmonary artery pressure-guided heart failure care: the setting matters</dc:title>
<dc:identifier>pmid:39027970</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae441</dc:identifier>
</item>
<item>
<title>Dissemination of the European Society of Cardiology clinical practice guidelines into the National Societies of Cardiology Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39027969/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240723141243&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 19:ehae424. doi: 10.1093/eurheartj/ehae424. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39027969/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240723141243&v=2.18.0.post9+e462414">39027969</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae424>10.1093/eurheartj/ehae424</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39027969</guid>
<pubDate>Fri, 19 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Michael Aschermann</dc:creator>
<dc:creator>Jean Jacques Monsuez</dc:creator>
<dc:creator>Goksel Cinier</dc:creator>
<dc:creator>Editors Network of the National Societies of Cardiology Journals, European Society of Cardiology</dc:creator>
<dc:date>2024-07-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Dissemination of the European Society of Cardiology clinical practice guidelines into the National Societies of Cardiology Journals</dc:title>
<dc:identifier>pmid:39027969</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae424</dc:identifier>
</item>
<item>
<title>Tailoring antithrombotic treatment in patients with acute myocardial infarction and cancer: virtue lies in balance</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39027965/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240723141243&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 19:ehae445. doi: 10.1093/eurheartj/ehae445. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39027965/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240723141243&v=2.18.0.post9+e462414">39027965</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae445>10.1093/eurheartj/ehae445</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39027965</guid>
<pubDate>Fri, 19 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Alfonso Jurado-Román</dc:creator>
<dc:creator>Pilar Agudo-Quílez</dc:creator>
<dc:date>2024-07-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Tailoring antithrombotic treatment in patients with acute myocardial infarction and cancer: virtue lies in balance</dc:title>
<dc:identifier>pmid:39027965</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae445</dc:identifier>
</item>
<item>
<title>Left atrial appendage closure for stroke prevention in atrial fibrillation: current status and perspectives</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39027946/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240723141243&amp;v=2.18.0.post9+e462414
      <description>Atrial fibrillation (AF) is associated with an increased risk of stroke and systemic embolism, and the left atrial appendage (LAA) has been identified as a principal source of thromboembolism in these patients. While oral anticoagulation is the current standard of care, LAA closure (LAAC) emerges as an alternative or complementary treatment approach to reduce the risk of stroke or systemic embolism in patients with AF. Moderate-sized randomized clinical studies have provided data for the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jul 19:ehae398. doi: 10.1093/eurheartj/ehae398. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Atrial fibrillation (AF) is associated with an increased risk of stroke and systemic embolism, and the left atrial appendage (LAA) has been identified as a principal source of thromboembolism in these patients. While oral anticoagulation is the current standard of care, LAA closure (LAAC) emerges as an alternative or complementary treatment approach to reduce the risk of stroke or systemic embolism in patients with AF. Moderate-sized randomized clinical studies have provided data for the efficacy and safety of catheter-based LAAC, largely compared with vitamin K antagonists. LAA device iterations, advances in pre- and peri-procedural imaging, and implantation techniques continue to increase the efficacy and safety of LAAC. More data about efficacy and safety of LAAC have been collected, and several randomized clinical trials are currently underway to compare LAAC with best medical care (including non-vitamin K antagonist oral anticoagulants) in different clinical settings. Surgical LAAC in patients with AF undergoing cardiac surgery reduced the risk of stroke on background of anticoagulation therapy in the LAAOS III study. In this review, we describe the rapidly evolving field of LAAC and discuss recent clinical data, ongoing studies, open questions, and current limitations of LAAC.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39027946/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240723141243&v=2.18.0.post9+e462414">39027946</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae398>10.1093/eurheartj/ehae398</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39027946</guid>
<pubDate>Fri, 19 Jul 2024 06:00:00 -0400</pubDate>
<dc:creator>Ulf Landmesser</dc:creator>
<dc:creator>Carsten Skurk</dc:creator>
<dc:creator>Apostolos Tzikas</dc:creator>
<dc:creator>Volkmar Falk</dc:creator>
<dc:creator>Vivek Y Reddy</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:date>2024-07-19</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Left atrial appendage closure for stroke prevention in atrial fibrillation: current status and perspectives</dc:title>
<dc:identifier>pmid:39027946</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae398</dc:identifier>
</item>





























</channel>
</rss>